BeiGene TEVIMBRA Combo OKd in U.S. for First-line Treatment of Gastric Cancers

 New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers

Second FDA approval for TEVIMBRA in 2024

https://www.businesswire.com/news/home/20241227403101/en/